Wall Street is underestimating vaccine maker Pfizer, which is primed for massive growth ahead as its Covid treatments will remain relevant for years—not to mention generate billions of dollars of revenue for the company, according to analysts at Wells Fargo.... [+]Wells Fargo recently initiated coverage of Pfizer with a “buy” rating and price target of $60 per share, implying an upside of around 16% from current levels.
Pfizer’s vaccine business alone could generate over $5 billion per year in revenue, the firm predicts, as COVID vaccines “will likely become an annual occurrence.”
I completely agree, COVID is the perfect business. The COVID investors have the Government and Social Media on their side; they keep redesigning their virus 🦠 and Terrorizing people all over the world 🌎 and legally supported against humanity just to make money 💰
South Africa South Africa Latest News, South Africa South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: WSJ - 🏆 98. / 63 Read more »